CHICAGO, April 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today the presentation of preclinical data demonstrating the significant anti-tumor activity of Interleukin-12 (IL-12) and interferon alpha (IFNa), two proteins involved in immune response to cancers, expressed in vivo utilizing a regulated gene system. The presentation was made at the 2012 American Association for Cancer Research (AACR) Annual Meeting, being held March 31 – April 4 in Chicago, IL, and was recognized as among the best science by the AACR Program Committee, a designation awarded to the top 2.5 percent of abstracts. The Committee designates meritorious presentations as “highly-rated” to assist attendees in identifying the best science at the meeting. ZIOPHARM is the exclusive channel partner to Intrexon Corporation, a privately held synthetic biology engineering company, in the discovery and development of DNA therapies in oncology.
